{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:28:01Z","timestamp":1786332481742,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is highly aggressive and difficult to manage due to its intrinsic resistance to oxidative stress. Nuclear factor erythroid 2-related factor 2 (NRF2), a master regulator of oxidative stress responses, is frequently overexpressed in ccRCC and is associated with poor prognosis. NRF2 promotes tumor progression by driving proliferation, metabolic reprogramming, and ferroptosis resistance; however, the upstream mechanisms controlling NRF2 stability remain incompletely understood. Here, we identify TSC22 domain family member 4 (TSC22D4) as a Kelch-like ECH-associated protein 1 (KEAP1)-interacting protein that directly binds to KEAP1 via a conserved ETGE motif. This interaction disrupts the KEAP1-NRF2 complex, preventing NRF2 ubiquitination and degradation, thereby enhancing NRF2 stability and activating antioxidant response element (ARE)-driven transcription. Notably, TSC22D4 upregulates solute carrier family 7 member 11 (SLC7A11), thereby suppressing ferroptosis and conferring resistance to sorafenib in ccRCC. TSC22D4 is markedly overexpressed in ccRCC and promotes tumor cell proliferation, invasion, and metastasis. Clinically, elevated TSC22D4 expression correlates with advanced disease stage and poor patient survival. In conclusion, TSC22D4 promotes ccRCC progression and sorafenib resistance by activating the KEAP1\u2013NRF2\u2013SLC7A11 axis and suppressing ferroptosis, highlighting TSC22D4 as a potential therapeutic target in ccRCC.<\/jats:p>","DOI":"10.1038\/s41419-026-08950-4","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:05:21Z","timestamp":1780628721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TSC22D4 drives clear cell renal cell carcinoma progression and therapy resistance by stabilizing NRF2 through KEAP1 disruption"],"prefix":"10.1038","volume":"17","author":[{"given":"Bohan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-7888","authenticated-orcid":false,"given":"Shancheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-6439","authenticated-orcid":false,"given":"Chenji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-5195","authenticated-orcid":false,"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-3182","authenticated-orcid":false,"given":"Anbang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"8950_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8950_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and the United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584\u201390.","journal-title":"Chin Med J"},{"key":"8950_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578\u201393.","journal-title":"Trends Mol Med"},{"key":"8950_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.semcancer.2021.05.016","volume":"76","author":"CJ Schmidlin","year":"2021","unstructured":"Schmidlin CJ, Shakya A, Dodson M, Chapman E, Zhang DD. The intricacies of NRF2 regulation in cancer. Semin Cancer Biol. 2021;76:110\u20139.","journal-title":"Semin Cancer Biol"},{"key":"8950_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","volume":"86","author":"H Sies","year":"2017","unstructured":"Sies H, Berndt C, Jones DP. Oxidative Stress. Annu Rev Biochem. 2017;86:715\u201348.","journal-title":"Annu Rev Biochem"},{"key":"8950_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2017.09.008","volume":"32","author":"W Ge","year":"2017","unstructured":"Ge W, Zhao K, Wang X, Li H, Yu M, He M, et al. iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding. Cancer Cell. 2017;32:561\u201373 e6.","journal-title":"Cancer Cell"},{"key":"8950_CR7","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1158\/0008-5472.CAN-16-2204","volume":"77","author":"K Lu","year":"2017","unstructured":"Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Mahdi A, et al. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res. 2017;77:2881\u201392.","journal-title":"Cancer Res"},{"key":"8950_CR8","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-22-4001","volume":"83","author":"K Chang","year":"2023","unstructured":"Chang K, Chen Y, Zhang X, Zhang W, Xu N, Zeng B, et al. DPP9 stabilizes NRF2 to suppress ferroptosis and induce sorafenib resistance in clear cell renal cell carcinoma. Cancer Res. 2023;83:3940\u201355.","journal-title":"Cancer Res"},{"key":"8950_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-021-00793-z","volume":"6","author":"C Da","year":"2021","unstructured":"Da C, Pu J, Liu Z, Wei J, Qu Y, Wu Y, et al. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells. Signal Transduct Target Ther. 2021;6:399.","journal-title":"Signal Transduct Target Ther"},{"key":"8950_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03042-7","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu C, et al. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. J Transl Med. 2021;19:367.","journal-title":"J Transl Med"},{"key":"8950_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03718-4","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, et al. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2\/GPX4 axis. Cell Death Dis. 2021;12:426.","journal-title":"Cell Death Dis"},{"key":"8950_CR12","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.cell.2021.04.011","volume":"184","author":"EL Huttlin","year":"2021","unstructured":"Huttlin EL, Bruckner RJ, Navarrete-Perea J, Cannon JR, Baltier K, Gebreab F, et al. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell. 2021;184:3022\u201340 e28.","journal-title":"Cell"},{"key":"8950_CR13","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-12-4400","volume":"73","author":"BE Hast","year":"2013","unstructured":"Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 2013;73:2199\u2013210.","journal-title":"Cancer Res"},{"key":"8950_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13267","volume":"7","author":"B Ekim Ustunel","year":"2016","unstructured":"Ekim Ustunel B, Friedrich K, Maida A, Wang X, Krones-Herzig A, Seibert O, et al. Control of diabetic hyperglycaemia and insulin resistance through TSC22D4. Nat Commun. 2016;7:13267.","journal-title":"Nat Commun"},{"key":"8950_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101487","volume":"60","author":"G Wolff","year":"2022","unstructured":"Wolff G, Sakurai M, Mhamane A, Troullinaki M, Maida A, Deligiannis IK, et al. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. Mol Metab. 2022;60:101487.","journal-title":"Mol Metab"},{"key":"8950_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/emmm.201201869","volume":"5","author":"A Jones","year":"2013","unstructured":"Jones A, Friedrich K, Rohm M, Schafer M, Algire C, Kulozik P, et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol Med. 2013;5:294\u2013308.","journal-title":"EMBO Mol Med"},{"key":"8950_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/febs.12123","volume":"280","author":"S Canterini","year":"2013","unstructured":"Canterini S, Carletti V, Nusca S, Mangia F, Fiorenza MT. Multiple TSC22D4 iso-\/phospho-glycoforms display idiosyncratic subcellular localizations and interacting protein partners. FEBS J. 2013;280:1320\u20139.","journal-title":"FEBS J"},{"key":"8950_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.bbrc.2019.11.145","volume":"522","author":"X Zhang","year":"2020","unstructured":"Zhang X, Koga N, Suzuki H, Kato M. Promotion of cellular senescence by THG-1\/TSC22D4 knockout through activation of JUNB. Biochem Biophys Res Commun. 2020;522:897\u2013902.","journal-title":"Biochem Biophys Res Commun"},{"key":"8950_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8950_CR20","doi-asserted-by":"crossref","unstructured":"Wang J, Guo D, Jiang S, Wu W, Gao X. Targeting ferroptosis in cancer: from mechanistic insights to therapeutic approaches. Mol Biomed. 2026;7:20.","DOI":"10.1186\/s43556-026-00416-5"},{"key":"8950_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688\u201392.","journal-title":"Nature"},{"key":"8950_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molmed.2023.05.013","volume":"29","author":"W Li","year":"2023","unstructured":"Li W, Liang L, Liu S, Yi H, Zhou Y. FSP1: a key regulator of ferroptosis. Trends Mol Med. 2023;29:753\u201364.","journal-title":"Trends Mol Med"},{"key":"8950_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VAN Kraft","year":"2020","unstructured":"Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Muller C, Zandkarimi F, et al. GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6:41\u201353.","journal-title":"ACS Cent Sci"},{"key":"8950_CR24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"TJ Hudson","year":"2010","unstructured":"International Cancer Genome C, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. International network of cancer genome projects. Nature. 2010;464:993\u20138.","journal-title":"Nature"},{"key":"8950_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2019.12.026","volume":"180","author":"DJ Clark","year":"2020","unstructured":"Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2020;180:207.","journal-title":"Cell"},{"key":"8950_CR26","first-page":"5175","volume":"17","author":"S Ji","year":"2019","unstructured":"Ji S, Xiong Y, Zhao X, Liu Y, Yu LQ. Effect of the Nrf2-ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma. Oncol Lett. 2019;17:5175\u201386.","journal-title":"Oncol Lett"},{"key":"8950_CR27","doi-asserted-by":"crossref","unstructured":"Guo M, Chen S, Sun J, Xu R, Qi Z, Li J, et al. PIP5K1A suppresses ferroptosis and induces sorafenib resistance by stabilizing NRF2 in hepatocellular carcinoma. Adv Sci. 2025;12:e04372.","DOI":"10.1002\/advs.202504372"},{"key":"8950_CR28","first-page":"2044","volume":"43","author":"H Huang","year":"2019","unstructured":"Huang H, Wu Y, Fu W, Wang X, Zhou L, Xu X, et al. Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression. Int J Mol Med. 2019;43:2044\u201354.","journal-title":"Int J Mol Med"},{"key":"8950_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/CAD.0000000000001416","volume":"34","author":"H Huang","year":"2023","unstructured":"Huang H, Zhang J, Jiang P, Xu X, Huang F, Zhao B, et al. FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating KEAP1\/Nrf2 signaling pathway. Anticancer Drugs. 2023;34:248\u201356.","journal-title":"Anticancer Drugs"},{"key":"8950_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04365-3","volume":"21","author":"H Liao","year":"2023","unstructured":"Liao H, Chang X, Gao L, Ye C, Qiao Y, Xie L, et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer. J Transl Med. 2023;21:828.","journal-title":"J Transl Med"},{"key":"8950_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103543","volume":"81","author":"Q Shi","year":"2025","unstructured":"Shi Q, Liu Y, Yang W, Li Y, Wang C, Gao K. The covalent modification of STAT1 cysteines by sulforaphane promotes antitumor immunity via blocking IFN-gamma-induced PD-L1 expression. Redox Biol. 2025;81:103543.","journal-title":"Redox Biol"},{"key":"8950_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4143\/crt.2024.818","volume":"57","author":"CH Song","year":"2025","unstructured":"Song CH, Choi Y, Kim N, Nam RH, Kim JW, Jang JY, et al. Sex-specific molecular markers NRF2 and PD-L1 in colon carcinogenesis: implications for right-sided colon cancer. Cancer Res Treat. 2025;57:1090\u2013103.","journal-title":"Cancer Res Treat"},{"key":"8950_CR33","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2019;179:964\u201383 e31.","journal-title":"Cell"},{"key":"8950_CR34","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.18632\/oncotarget.14492","volume":"8","author":"FP Fabrizio","year":"2017","unstructured":"Fabrizio FP, Costantini M, Copetti M, la Torre A, Sparaneo A, Fontana A, et al. Keap1\/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget. 2017;8:11187\u201398.","journal-title":"Oncotarget"},{"key":"8950_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5555","volume":"8","author":"S Demir","year":"2022","unstructured":"Demir S, Wolff G, Wieder A, Maida A, Buhler L, Brune M, et al. TSC22D4 interacts with Akt1 to regulate glucose metabolism. Sci Adv. 2022;8:eabo5555.","journal-title":"Sci Adv"},{"key":"8950_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116822","volume":"279","author":"B Lv","year":"2024","unstructured":"Lv B, Xing S, Wang Z, Zhang A, Wang Q, Bian Y, et al. NRF2 inhibitors: recent progress, future design and therapeutic potential. Eur J Med Chem. 2024;279:116822.","journal-title":"Eur J Med Chem"},{"key":"8950_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cells14100713","volume":"14","author":"SK Hasan","year":"2025","unstructured":"Hasan SK, Jayakumar S, Espina Barroso E, Jha A, Catalano G, Sandur SK, et al. Molecular targets of oxidative stress: focus on nuclear factor erythroid 2-related factor 2 function in leukemia and other cancers. Cells. 2025;14:713.","journal-title":"Cells"},{"key":"8950_CR38","doi-asserted-by":"publisher","first-page":"45.","DOI":"10.3892\/ijo.2024.5633","volume":"64","author":"B Zeng","year":"2024","unstructured":"Zeng B, Wan R, Chang K, Li J, Zhang X, Shi G, et al. Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis. Int J Oncol. 2024;64:45.","journal-title":"Int J Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08950-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:33:29Z","timestamp":1786329209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08950-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8950"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08950-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"702"}}